U.S. patent application number 15/015721 was filed with the patent office on 2016-06-09 for systems and methods for fixating transvenously implanted medical devices.
This patent application is currently assigned to CARDIAC PACEMAKERS, INC.. The applicant listed for this patent is CARDIAC PACEMAKERS, INC.. Invention is credited to G. Shantanu Reddy.
Application Number | 20160158561 15/015721 |
Document ID | / |
Family ID | 39666116 |
Filed Date | 2016-06-09 |
United States Patent
Application |
20160158561 |
Kind Code |
A1 |
Reddy; G. Shantanu |
June 9, 2016 |
SYSTEMS AND METHODS FOR FIXATING TRANSVENOUSLY IMPLANTED MEDICAL
DEVICES
Abstract
A transvenously implantable medical device (TIMD) includes an
electrical lead and a control module. The electrical lead includes
one or more electrodes and is adapted for transvenous implantation.
The electrical lead is also pre-biased to expand from a collapsed
state to an expanded state to mechanically engage an internal wall
of a blood vessel. The control module is secured to and in
electrical communication with the electrical lead. The control
module includes a signal management component and a power component
disposed in a housing adapted for implantation into the blood
vessel. The control module is adapted for at least one of
stimulating and sensing a physiologic response using the one or
more electrodes of the electrical lead.
Inventors: |
Reddy; G. Shantanu;
(Minneapolis, MN) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
CARDIAC PACEMAKERS, INC. |
St. Paul |
MN |
US |
|
|
Assignee: |
CARDIAC PACEMAKERS, INC.
St. Paul
MN
|
Family ID: |
39666116 |
Appl. No.: |
15/015721 |
Filed: |
February 4, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14336308 |
Jul 21, 2014 |
|
|
|
15015721 |
|
|
|
|
13338924 |
Dec 28, 2011 |
8798770 |
|
|
14336308 |
|
|
|
|
11750185 |
May 17, 2007 |
8103359 |
|
|
13338924 |
|
|
|
|
Current U.S.
Class: |
607/32 ;
607/60 |
Current CPC
Class: |
A61N 1/37205 20130101;
A61N 1/362 20130101; A61N 2001/0585 20130101; A61N 1/0573 20130101;
A61N 1/37516 20170801; A61N 1/056 20130101; A61N 1/37512 20170801;
A61N 1/3756 20130101; A61N 1/3702 20130101; A61N 1/057 20130101;
A61N 1/37217 20130101 |
International
Class: |
A61N 1/372 20060101
A61N001/372; A61N 1/37 20060101 A61N001/37; A61N 1/05 20060101
A61N001/05 |
Claims
1. A medical system, comprising: a first device configured to
transmit an optical trigger signal; and an implantable medical
device (IMD) configured to receive the optical trigger signal and
to initiated delivery of a therapy to a patient in response to
receiving the optical trigger signal.
2. The medical system of claim 1, wherein the therapy comprises
electrical stimulation therapy.
3. The medical system of claim 1, wherein the IMD is configured to
initiate delivery of an electrical stimulation therapy to a
targeted body tissue of the patient via a pair of electrodes of the
IMD in response to receiving the optical trigger signal.
4. The medical system of claim 1, wherein the IMD is an implantable
cardiac pacemaker.
5. The medical system of claim 1, wherein the first device is an
implantable medical device.
6. The medical system of claim 5, wherein the first device is an
implantable cardiac stimulation device.
7. The medical system of claim 6, wherein the first device is
external of the patient.
8. The medical system of claim 1, wherein the IMD further comprises
sensing functionality, wherein the first device is configured to
communicate with the IMD to control the sensing functionality of
the IMD.
9. A method for delivering therapy to a patient, comprising:
transmitting an optical trigger signal from a first device into the
body of the patient so as to reach an implanted second device;
detecting the optical trigger signal at the implanted second
device; and delivering a therapy to the patient via the implanted
second device in response to detecting the optical trigger signal
at the implanted second device.
10. The method of claim 9, wherein the therapy comprises electrical
stimulation therapy.
11. The method of claim 9, wherein the implanted second device
initiates delivery of an electrical stimulation therapy to a
targeted body tissue of the patient via a pair of electrodes of the
implanted second device in response to detecting the optical
trigger signal from the first device.
12. The method of claim 9, wherein the implanted second device is
an implanted cardiac stimulation device.
13. The method of claim 12, wherein the implanted second device is
a pacemaker.
14. The method of claim 9, wherein the first device is an
implantable medical device.
15. The method of claim 14, wherein the first device is an
implantable cardiac stimulation device.
16. The method of claim 9, further comprising: establishing a
communication path between the first device and the an implanted
second device via one or more of radiofrequency, acoustic or
optical communication; and controlling a sensing functionality of
the implanted second device via the established communication
path.
17. An implantable medical device comprising: an optical receiver;
two or more electrodes for delivering electrical stimulation
therapy to a targeted body tissue of a patient; a control module
operatively coupled to the optical receiver and the two or more
electrodes, the control module configured to: detect an optical
trigger signal received via the optical receiver; and deliver the
electrical stimulation therapy to the targeted body tissue of the
patient in response to detecting the optical trigger signal.
18. The implantable medical device of claim 17, wherein the control
module is further configured to implement a sensing functionality
using the two or more electrodes.
19. The implantable medical device of claim 18, wherein the control
module is configured to change the sensing functionality based on
one or more signals received from a remotely located device.
20. The implantable medical device of claim 17, wherein electrical
stimulation therapy includes one or more electrostimulation pulse.
Description
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application is a continuation of U.S. application Ser.
No. 14/336,308, filed on Jul. 21, 2014, which is a continuation of
U.S. application Ser. No. 13/338,924, filed on Dec. 28, 2011, now
U.S. Pat. No. 8,798,770, which is a continuation of U.S.
application Ser. No. 11/750,185, filed on May 17, 2007, now U.S.
Pat. No. 8,103,359, all of which are herein incorporated by
reference in their entirety.
TECHNICAL FIELD
[0002] The present invention relates to management of physiological
functions utilizing wireless implants. More specifically, the
invention relates to transvenously implanting and fixating a
wireless implant within vasculature of a person.
BACKGROUND
[0003] Various physiological functions can be managed utilizing
minute, wireless implants that operate individually or as part of a
larger system. Wireless implants can provide sensing or stimulating
functionality to assist with a person's health. For example,
wireless implants have been discussed in association with cardiac
management, including wireless electrodes used to stimulate cardiac
muscle for assisted cardiac pacing. Wireless implant configuration,
deployment, and fixation within the body provide an array of both
recognized and yet-to-be realized problems.
SUMMARY
[0004] One embodiment of a transvenously implantable medical device
(TIMD) includes an electrical lead and a control module. The
electrical lead includes one or more electrodes and is adapted for
transvenous implantation. The electrical lead is also pre-biased to
expand from a collapsed state to an expanded state to mechanically
engage an internal wall of a blood vessel. The control module is
secured to and in electrical communication with the electrical
lead. The control module includes a signal management component and
a power component disposed in a housing adapted for implantation
into the blood vessel. The control module is adapted for at least
one of stimulating and sensing a physiologic response using the one
or more electrodes of the electrical lead.
[0005] One embodiment of a method of transvenous implantation
includes collapsing a first lead, the first lead including an
elongate lead body secured to a control module and at least one
electrode in electrical communication with the control module. The
control module and the first lead are transvenously implanted into
a blood vessel. The first lead is expanded to engage an inner wall
of the blood vessel such that the control module and the first lead
are anchored in the blood vessel.
[0006] While multiple embodiments are disclosed, still other
embodiments of the present invention will become apparent to those
skilled in the art from the following detailed description, which
shows and describes illustrative embodiments of the invention.
Accordingly, the drawings and detailed description are to be
regarded as illustrative in nature and not restrictive.
BRIEF DESCRIPTION OF THE DRAWINGS
[0007] FIG. 1 shows an exemplary transvenously implantable medical
device (TIMD) accessing a patient's heart according to embodiments
of the present invention.
[0008] FIG. 1A is an enlarged view showing the TIMD of FIG. 1 in
greater detail.
[0009] FIG. 2 is a schematic of the TIMD of FIG. 1.
[0010] FIG. 3 shows a cross-section of a portion of a lead of the
TIMD of FIG. 1.
[0011] FIGS. 4-6 are illustrative of an exemplary method of
transvenously implanting the TIMD of FIG. 1 in a blood vessel
according to embodiments of the present invention.
[0012] FIGS. 7 and 8 show another exemplary TIMD according to
embodiments of the present invention.
[0013] FIGS. 9 and 10 show another exemplary TIMD and method of
transvenously implanting the TIMD according to embodiments of the
present invention.
[0014] FIG. 11 is illustrative of another method of transvenously
implanting the TIMD of FIGS. 9 and 10 according to embodiments of
the present invention.
[0015] FIG. 12 shows another exemplary TIMD according to
embodiments of the present invention.
[0016] While the invention is amenable to various modifications and
alternative forms, specific embodiments have been shown by way of
example in the drawings and are described in detail below. The
intention, however, is not to limit the invention to the particular
embodiments described. On the contrary, the invention is intended
to cover all modifications, equivalents, and alternatives falling
within the scope of the invention as defined by the appended
claims.
DETAILED DESCRIPTION
[0017] FIGS. 1 and 1A show a transvenously implantable medical
device (TIMD) 10 according to embodiments of the present invention,
where FIG. 1A is an enlarged view showing the TIMD 10 in greater
detail. The TIMD 10 is adapted to be implanted transvenously at a
desired location within the vasculature of the patient. In some
embodiments, the TIMD 10 is implanted within vasculature of the
heart 12 to provide cardiac sensing and/or stimulation
functionality. For example, the TIMD 10 can be used to sense
various physiological characteristics of the heart 12 and/or to
transmit a stimulating pulse of energy to tissue of the heart 12,
such as the tissue forming the left ventricle 14.
[0018] In some embodiments, the TIMD 10 is adapted to be implanted
into the right atrium 16, through the coronary sinus ostium 18 and
into the coronary sinus 20 of the heart 12. As is subsequently
described, catheter-based implantation is contemplated in
association with the TIMD 10. The TIMD 10 is implantable within the
left marginal vein 22 (as shown), or any other branch vein of the
coronary sinus 20, including any of those known in the art of
cardiac management. For example, the TIMD 10 is optionally
implanted within the great cardiac vein 24, the middle cardiac vein
26, the left posterior ventricular vein 28, the small cardiac vein
30, or others.
[0019] Although the TIMD 10 is implanted in vasculature of the
heart 12 in some embodiments, the TIMD 10 can also be implanted at
other intravenous locations and/or to perform other functions. For
example, the TIMD 10 is optionally implanted in vasculature of the
neck, such as one of the jugular veins. The TIMD 10 can perform
various functions from the jugular veins, such as cardiac rhythm
management via vagal nerve stimulation, for example. As another
example, the TIMD 10 is optionally implanted in peripheral
vasculature and is adapted for acquiring diagnostic information,
blood pressure for example, and then storing the diagnostic
information, transmitting the diagnostic information to another
implanted medical device (IMD), and/or transmitting the diagnostic
information to an external device.
[0020] In some embodiments, the TIMD 10 is usable with a wireless
electrode system 40 that includes a control system 42 having a
transmitter 44 for communicating with one or more wireless
electrodes, such as the TIMD 10. In one embodiment, the transmitter
44 is an inductive coil used to inductively charge the TIMD 10 with
power and/or trigger delivery of stimulating energy from the TIMD
10 to the heart 12. In other embodiments, the transmitter 44 is a
radiofrequency communication device, an acoustic communication
device, or other device for communicating with the TIMD 10.
[0021] In some embodiments, the control system 42 directly controls
stimulation via the TIMD 10 from outside of the body (externally,
for example worn about the neck) or from within the body
(internally, for example implanted similarly to a conventional
pacemaker) using inductive communication/power transmission. The
control system 42 can also use other types of communication to
directly control stimulation or sensing functionality administered
with the TIMD 10 in addition to or as an alternative to inductive
transmission. For example, radiofrequency, optical, or acoustic
communication between the TIMD 10 and the control system 42 are
also contemplated. Examples of various wireless electrode systems
usable in association with the TIMD 10 are described in U.S. Patent
App. Pub. 2006/0085039, "Leadless Cardiac Stimulation Systems," and
U.S. Patent App. Pub. 2003/0158584, "Chronically-Implanted Device
for Sensing and Therapy," the entire contents of each of which are
incorporated herein by reference.
[0022] In some embodiments, the control system 42 and the TIMD 10
are optionally deployed in a satellite-planet configuration, where
the control system 42 acts as a planet device and the TIMD 10, or a
plurality of devices similar to the TIMD 10, act as one or more
satellite device(s). The TIMD 10 and control system 42 can have
varying degrees of control over sensing/stimulating operation of
the TIMD 10. In some embodiments, the TIMD 10 is programmed to
manage cardiac stimulation for a substantial period of time.
Examples of wireless, implanted electrodes that are programmable to
control stimulating or sensing functionality, as well as examples
of satellite-planet device configurations are described in
previously-incorporated U.S. Patent App. Pub. 2003/0158584.
[0023] FIG. 2 is a schematic view of the TIMD 10 in an unassembled
state. The TIMD 10 includes a control module 50 and an electrical
lead 52 providing means for fixating the control module 50 within
vasculature. The control module 50 includes a housing 60 and
various electrical components, including a signal management
component 62, a power component 64, and a communication component
66. Various components of the control module 50, including
components 62, 64, 66 can be arranged as discrete devices, combined
devices having shared circuits and/or processing capabilities, or
according to other arrangements.
[0024] The housing 60 is adapted for transvenous delivery and
implantation in human vasculature, including vasculature associated
with the heart 12. The housing 60 is formed of metallic, polymeric,
or other biocompatible materials. In one embodiment, the housing 60
is substantially oblong and forms a terminal connector 70 adapted
to be secured to the lead 52, a hermetically sealed interior
compartment 72 adapted to house and protect the components 62, 64,
66, and an inner lumen 74 (shown in dotted lines) extending
longitudinally through the housing 60. The inner lumen 74 is
generally adapted to facilitate implantation of the TIMD 10, as
described subsequently in greater detail. In some embodiments, the
housing 60 includes drug delivery features, e.g., a steroid collar,
drug eluting coating, or other therapeutic agents, or others. The
housing 60 also optionally includes stimulating and/or sensing
features, e.g., one or more electrodes associated with the housing
60.
[0025] The signal management component 62 includes circuitry for
managing operation of the TIMD 10. In some embodiments, the signal
management component 62 controls delivery of stimulating energy
from the TIMD 10. The signal management component 62 is optionally
adapted to be programmed to execute various stimulation or sensing
programs. In other embodiments, the signal management component 62
is a hardwired circuit configured to deliver set stimulation or
sensing programs upon initiation by a remote controller, such as
the control system 42 (FIG. 1).
[0026] The power component 64 operates to provide power to the
signal management component 62 and/or the communication component
66. In various embodiments, the power component 64 is a battery, a
coil for receiving a charge through inductance, or other type of
power source for providing energy to the TIMD 10. In some
embodiments, power is transmitted to the control module 50 from an
outside source, including those internal or external to the body,
such as the control system 42 (FIG. 1). If desired, the power
component 64 is optionally integrated with the communication
component 66 and data being transmitted to and received by the
control module 50 is encoded into the power transmission as a
modulation of the power signal from the control system 42. Examples
of integrated power/communication arrangements are described in
previously incorporated U.S. Patent App. Pub. 2003/0158584.
[0027] The communication component 66 serves to provide a
communication link between the TIMD 10 and one or more other
devices, such as the control system 42 (FIG. 1), that are internal
and/or external to the patient. The communication component 66
includes circuitry and/or other structures for providing
communication between the chronically-implanted device and another
device using radio-frequency (RF) waves, acoustics, or inductance,
for example. In some embodiments, the communication component 66
includes an acoustic transmitter for transmitting an acoustic
signal to another device, such as the control system 42. For
example, the control system 42 is optionally an implanted cardiac
stimulus device, such as a pacemaker and the communication
component 66 is adapted to provide bidirectional communication
between the TIMD 10 and the control system 42.
[0028] The lead 52 defines a central longitudinal axis X and
includes a lead body 80 extending from a terminal connector end 82
to a distal end 84. FIG. 3 shows a cross-section of a portion of
the lead 52 along the line 3-3 shown in FIG. 2. As shown in FIGS. 2
and 3, the lead body 80 includes an outer, insulating sheath 88, an
inner, conductive core 90, an inner, insulating sheath 92, and one
or more electrodes 98. The electrodes 98 include a plurality of
ring electrodes 100 disposed circumferentially about the lead body
80 and a tip electrode 102 located at the distal end 84.
[0029] The conductive core 90 is sandwiched between the outer and
inner insulating sheaths 88, 92 and is optionally of a coiled
design. The inner sheath 92 defines a lumen 104 that is open at the
terminal connector end 82. As shown, the electrodes 98 are
positioned along the lead body 80. The electrodes 98 are in
electrical communication with the conductive core 90, providing an
electrical pathway between the electrodes 98 and the control module
50. In some embodiments, the core 90 is a coiled core, although
other configurations are contemplated. For example, in other
embodiments, the core 90 is a cable or ribbon conductor. The
conductive core 90 can be made of any electrically conductive
materials.
[0030] In some embodiments, the lead 52 includes no lumens or
greater number of lumens 104, a non-coiled conductive core 90, or
other features associated with electrical leads. For example, in
some embodiments, a steroid collar is employed with the lead 52 to
help ensure proper pacing and/or as a therapeutic agent, including
anti-inflammatories, antithrombogenics, antiproliferatives, or
other types of therapeutic agents. Examples of various electrical
lead features contemplated for use with the lead 52 are described
in U.S. Pat. No. 6,584,362, "Leads for Pacing and/or Sensing the
Heart from within the Coronary Veins," the entire contents of which
are incorporated herein by reference.
[0031] The electrodes 98 can be substantially the same as known
electrodes for pacing and/or defibrillation leads. The electrodes
98 are formed of an electrically conductive material such as an
alloy of platinum and iridium which is highly conductive and highly
resistant to corrosion. In operation, the conductive core 90
carries electrical current between the control module 50 and the
electrodes 98. As shown, the lead 52 is unipolar with a single
conductor. In other embodiments, the lead 52 is bipolar where one
or more of the electrodes 98 are each in electrical communication
with a plurality of separate conductors (not shown).
[0032] The lead 52 is pre-biased to define a first shape in an
expanded state (FIG. 2) and can be transitioned, or collapsed, to
define a second shape in a collapsed state (FIG. 4). As shown in
FIG. 2 and FIG. 4, the lead 52 has a substantially larger maximum
outer dimension in the expanded state than in the collapsed state.
In different terms, the lead 52 defines a larger profile relative
to the central longitudinal axis X of the lead 52 when the lead is
in the expanded state in comparison to when the lead 52 is in the
collapsed state.
[0033] As shown in FIG. 2, in the expanded state, the lead 52
naturally extends through an arcuate path to define a substantially
helical, or coiled shape. As will be described in greater detail,
other expanded state shapes are also contemplated, including
generally arcuate shapes, undulating shapes, sinusoidal shapes,
circular shapes, and others. The lead 52 is pre-formed, or
otherwise pre-biased to the shape exhibited in the expanded state
via heat-setting, materials selection, plastic deformation of the
conductive core 90, or using another technique known in the
art.
[0034] As shown in FIG. 4, the lead 52 is straighter, or more
linear, in the collapsed state than in the expanded state according
to some embodiments. Various collapsed state shapes are
contemplated, including helical shapes having a smaller transverse
profile than in the expanded state.
[0035] One manner of assembling the control module 50 to the lead
52 is described with reference to FIGS. 2, 3, and 4. In particular,
the control module 50 is assembled to the lead 52 by securing the
terminal connector end 82 of the lead 52 to the terminal connector
70 of the control module 50. Upon assembly, the conductive core 90
(FIG. 3) of the lead 52 is placed in electrical communication with
the components of the control module 50 such that the signal
management component 62 (FIG. 2) of the module 50 can send a
stimulation signal to, or receive a sensing signal from, the
electrodes 98 through the conductive core 90 of the lead 52.
Additionally, the inner lumen 104 (FIG. 3) of the lead 52 is
coaxially aligned to the inner lumen 74 (FIG. 2) of the control
module 50 to form a longitudinal passageway through the control
module 50 into the lead 52. In one embodiment, the lead 52 has
specific biases to facilitate placement and retention of the lead
52 in the coronary sinus 20 (FIG. 1) or a branch vessel
thereof.
[0036] FIGS. 4-6 are illustrative of one embodiment method of
transvenously implanting the TIMD 10 in a blood vessel 150 having a
vessel wall 152. FIG. 4 shows the TIMD 10 with the lead 52 in a
collapsed state. In particular, a straightening member 160, such as
a stylet or a guidewire having sufficient stiffness to straighten
and maintain the lead 52 in the collapsed state, is inserted
through the inner lumen 74 of the control module 50 into the lead
52 to collapse the lead 52.
[0037] The TIMD 10 and straightening member 160 are delivered to a
desired transvenous implantation site, for example in the coronary
sinus 20 (FIG. 1) or a branch vein thereof. In some embodiments,
the TIMD 10 and the straightening member 160 are delivered through
a guide catheter 162 as shown in FIG. 4. When the guide catheter
162 is used, the TIMD 10 is deployed from the guide catheter 162
once the TIMD 10 is delivered proximate a desired location within
the blood vessel 150. In other embodiments, the TIMD 10 is
delivered directly to the desired implantation site using the
straightening member 160 and in the absence of the guide catheter
162 in a manner substantially similar to an over-the-wire lead
delivery technique.
[0038] The straightening member 160 is then removed from the TIMD
10. If desired, a secondary member 164 can be deployed over the
straightening member 160 to press against the TIMD 10 to assist
with deployment of the TIMD 10 from the guide catheter 162 and/or
removal of the straightening member 160 from the TIMD 10. In some
embodiments, the secondary member 164 is catheter-like in
construction and formed according to catheter-based manufacturing
methods.
[0039] As the straightening member 160 is removed, the lead 52
transitions from the collapsed state to the expanded state shown in
FIGS. 5 and 6 to contact the vessel wall 152. The lead 52 provides
means for anchoring or fixating the TIMD 10 in the blood vessel
150. In particular, the maximum outer dimension of the lead 52, for
example the transverse diameter defined by the helical shape of the
lead 52, is selected such that the lead 52 will mechanically engage
the vessel wall 152. The mechanical engagement between the lead 52
and the vessel wall 152 is used to place one or more of the
electrodes 98 in electrical communication with the vessel wall 152
and to anchor or otherwise fixate the TIMD 10 in position within
the blood vessel 150. In various embodiments, the lead 52 includes
coatings, e.g., fibrosis encouraging coatings, or surface features
to enhance frictional engagement with the vessel wall 152. In other
embodiments, the lead 52 includes anti-fibrosis coatings or
treatments to discourage fibrosis and facilitate lead extraction.
As shown in FIG. 6, upon expansion the TIMD 10 defines a central
passage 168 through the expanded shape of the TIMD 10. In some
embodiments, the central passage 168 facilitates blood flow past
the TIMD 10.
[0040] Once disposed within the blood vessel 150, the TIMD 10 is
used for sensing or stimulation according to various embodiments.
For example, the blood vessel 150 is optionally the coronary sinus
20 (FIG. 1) or one of the branch vessels thereof. The electrodes 98
of the TIMD 10 can then be used to transmit a pulse of stimulating
energy through the vessel wall 152 to surrounding tissue of the
heart 12.
[0041] According to some methods of transvenous implantation, the
TIMD 10 is re-collapsible following transvenous implantation to
remove or reposition the TIMD 10. For example, the secondary member
164 can be used to grip the control module 50 following
implantation of the TIMD 10. In some embodiments, a vacuum is
applied through the secondary member 164, which secures the control
module 50 to the secondary member 164. The control module 50
optionally includes a proximal seal 170 that is able to be engaged
by the secondary member 164. In one embodiment, the proximal seal
170 facilitates coupling of the control module 50 to the secondary
member 164 via application of negative pressure through the
secondary member 164 by forming a better seal between the control
module 50 and the secondary member 164.
[0042] In other embodiments, the secondary member 164 includes
gripping elements (not shown), somewhat like jaws of a pliers, for
gripping the control module 50 or associated structures. In still
other embodiments, the control module 50 includes a wire loop (not
shown) and the secondary member 164 includes a hook (not shown) for
grasping the loop. Other means for securing the control module 50
relative to the secondary member 164 are also contemplated,
including detents, magnets, adhesives, male and female threads, and
others.
[0043] Once the secondary member 164 is secured to the control
module 50, the straightening member 160 is reinserted into the
lumen 104 of the lead 52 through the inner lumen 74 of the control
module 50. As the straightening member 160 is reintroduced into the
lead 52, the lead 52 transitions to the collapsed state, and out of
mechanical engagement with the vessel wall 152. Once the lead 52
has been partially or fully collapsed, the TIMD 10 is able to be
removed or repositioned as desired.
[0044] FIGS. 7 and 8 show another TIMD 200 according to some
embodiments of the invention. The TIMD 200 includes a control
module 210 and an electrical lead 220 providing means for fixating
the control module 210 within vasculature. In some embodiments, the
control module 210 and the lead 220 include substantially similar
components as the control module 50 and the lead 52 of the TIMD 10.
The lead 220 extends through an arcuate path and is curved or
biased, being adapted to expand from a collapsed state (not shown),
for example substantially straight, to an expanded state, for
example having the curvatures shown in FIGS. 7 and 8. Similarly to
the TIMD 10, the lead 220 of the TIMD 200 defines a substantially
larger maximum outer dimension in the expanded state than in the
collapsed state.
[0045] As shown in FIG. 7, the curvature of the lead 220 is
primarily in two dimensions, or within a single plane. As shown in
FIG. 8, the curvature of lead 220 also includes a non-planar
component, with a second bend or curve in a second plane. The lead
220 is pre-formed, or otherwise pre-biased to the expanded state
via heat-setting, materials selection, plastic deformation, or
others. In some embodiments, the lead 220 is constructed and
arranged for fixation in the coronary sinus 20, and is pre-biased
to facilitate placement and retention in the coronary sinus 20, or
a branch vessel thereof. Various examples of structures and methods
for providing such pre-biased, curved shapes are described in
co-pending U.S. patent application Ser. No. 11/277,326, filed Mar.
23, 2006, and entitled "Left Ventricular Lead Shapes," the entire
contents of which are incorporated herein by reference.
[0046] In some embodiments, the TIMD 200 is transvenously implanted
in a similar manner to the TIMD 10, for example using the guide
catheter 162 (FIG. 4), the secondary member 164 (FIG. 4), and/or
the straightening member 160 (FIG. 4) as previously described. Once
implanted, the lead 220 is transitioned from the collapsed state to
the expanded state to contact the vessel wall 152 (FIG. 4). The
maximum outer dimension of the lead 220, for example the outer
diameter defined by the arcuate shape of the lead 52, is selected
such that the lead 52 will mechanically engage the vessel wall 152
to anchor the TIMD 200 in the blood vessel 150. The TIMD 200 can
also be removed from the blood vessel 150 in a similar manner to
that described in association with the TIMD 10 according to some
embodiments.
[0047] FIGS. 9 and 10 show another TIMD 300 according to some
embodiments of the invention and are illustrative of one method of
transvenously implanting the TIMD 300. The TIMD 300 includes a
control module 310 and an electrical lead 320 providing means for
fixating the control module 310 within vasculature. The lead 320 is
adapted to transition between a collapsed state and an expanded
state. In some embodiments, the control module 310 and the lead 320
include substantially similar components as the control module 50
and the lead 52 of the TIMD 10. The control module 310 optionally
includes one or more electrodes 315 for performing sensing and/or
stimulating functions similar to those previously described. In
some embodiments, the electrode 315 is used in conjunction with one
or more electrodes of the lead 320.
[0048] As shown in FIGS. 9 and 10, the control module 310 has a
proximal end 330 and distal end 332 and the lead 320 has a first
end 334 and a second end 336. The first end 334 of the lead 320 is
secured to the proximal end 330 of the control module 310 while the
second end 336 of the lead 320 is secured to the distal end 332 of
the control module 310. The lead 320 extends through an arcuate
shape from the proximal end 330 to the distal end 332 of the
control module 310.
[0049] FIG. 9 shows the lead 320 in the collapsed state, where the
lead 320 has been pressed into a more compact, linear shape than in
the expanded state (FIG. 10). FIG. 10 shows the lead 320 in the
expanded state, where the lead 320 defines a greater height, or
outer diameter in the expanded state than in the collapsed state.
In different terms, in the expanded state the lead 320 has a
substantially larger maximum outer dimension than in the collapsed
state. The lead 320 is pre-formed, or otherwise pre-biased to the
shape exhibited in the expanded state via heat-setting, materials
selection, plastic deformation to impart a curvature, or
others.
[0050] One method of transvenously implanting the TIMD 300 is also
generally illustrated in FIGS. 9 and 10. As shown in FIG. 9, the
lead 320 is maintained in the collapsed state within a catheter
350. The catheter 350 is guided to a desired position within the
blood vessel 150. Once the TIMD 300 is positioned proximate to the
desired position for implantation, a pusher 352 is used to eject
the TIMD 300 from the catheter 350. Once the external force of the
catheter 350 is removed from the TIMD 300, the TIMD 300 transitions
to the expanded state as shown in FIG. 10 to engage the vessel wall
152 and anchor the TIMD 300 in place. Although the TIMD 300 is
shown oriented "sideways" within the blood vessel 150, other
orientations are also contemplated. For example, the TIMD 300 is
optionally transvenously implanted as shown in FIG. 11, where the
TIMD 300 is oriented substantially coaxially with the blood vessel
150.
[0051] FIG. 12 shows another exemplary TIMD 400 according to
embodiments of the present invention. The TIMD 400 includes a
control module 410, a first electrical lead 420, and a second
electrical lead 422, the first and second leads 420, 422 providing
means for fixating the control module 410 within vasculature. The
first and second leads 420, 422 are adapted to transition between a
collapsed state and an expanded state. In some embodiments, the
control module 410 and the leads 420, 422 generally include
substantially similar components as the control module 50 and the
lead 52 of the TIMD 10 (FIG. 1).
[0052] As shown in FIG. 12, the control module 410 has a proximal
end 430 and distal end 432. The first lead 420 has a first end 434
and a second end 436. The second lead 422 has a first end 438 and a
second end 440. The first ends 434, 438 of the leads 420, 422 are
secured to the proximal end 430 of the control module 410 while the
second ends 436, 440 of the leads 420, 422 are secured to the
distal end 432 of the control module 410. The first and second
leads 420, 422 extend through opposing, arcuate paths relative to
the control module 410 to define a pair of semi-circular
shapes.
[0053] The leads 420, 422 are transitionable between an expanded
state and a more compact, collapsed state. FIG. 12 shows the leads
420, 422 in the expanded state. As described in association with
other embodiments, the leads 420, 422 are pre-biased to the
expanded state such that they will expand outwardly to the shape
shown generally in FIG. 12. The leads 420, 422 are sufficiently
flexible to be compressed to a collapsed state where the leads 420,
422 define a more linear, compact shape. In particular, the leads
420, 422 are pressed inwardly toward the control module 410 in the
collapsed state. As described in association with other
embodiments, the leads 420, 422 define a greater height, or overall
outer diameter in the expanded state than in the collapsed state.
The leads 420, 422 are pre-biased to the expanded state shape via
heat-setting, materials selection, plastic deformation, or
others.
[0054] The TIMD 400 can also include means for transitioning the
TIMD 400 to the collapsed state. In some embodiments, the TIMD 400
includes a filament 450 that can be tensioned to collapse the first
and second leads 420, 422 toward the control module 410. The
filament 450 includes a loop 452 at the proximal end 430 of the
control module 410. The filament 450 extends from the loop 452
through the control module 410 and splits into a first leg 454 and
a second leg 456. The first leg 454 is secured to the first lead
420 while the second leg 456 is secured to the second lead 422. In
operation, the loop 452 is pulled, which in turn tensions the first
and second legs 454, 456, collapsing the leads 420, 422.
[0055] The TIMD 400 is transvenously implanted in a similar manner
as that described in association with the TIMD 300. For example,
the catheter 350 is optionally used to maintain the TIMD 400 in the
collapsed state. The pusher 352 is then optionally used to eject
the TIMD 400 from the catheter 350. Once the external force of the
catheter 350 is removed from the TIMD 400, the TIMD 400 transitions
to the expanded state as shown in FIG. 12 to engage the vessel wall
152 and anchor the TIMD 400 in place.
[0056] In some embodiments, the TIMD 400 is removed from the blood
vessel 150 (FIG. 10) by fully or partially collapsing the leads
420, 422 toward the control module 410 using the filament 450. For
example, a catheter or other device (not shown) having gripping
jaws or a hook is used to pull the filament 450 by hooking, or
grasping the loop 452 and pulling on the loop 452. Upon tensioning
the filament 450, the TIMD 400 is transitioned to the collapsed
state and is repositioned as desired or removed entirely from the
blood vessel 150. The various TIMD embodiments previously described
can also include a filament forming a loop similar to the filament
450 and loop 452 to provide means for grasping and/or collapsing
the TIMDs associated with those embodiments.
[0057] Various modifications and additions can be made to the
exemplary embodiments discussed without departing from the scope of
the present invention. For example, while the embodiments described
above refer to particular features, the scope of this invention
also includes embodiments having different combinations of features
and embodiments that do not include all of the described features.
Accordingly, the scope of the present invention is intended to
embrace all such alternatives, modifications, and variations as
fall within the scope of the claims, together with all equivalents
thereof.
* * * * *